AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Confe ...

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe. Pediatric Endocrine Society (PES) Annual Meeting, held May 2-5, 2024, in Chicago, IL Abstract, OraGrow ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2023. OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in its Charter) Delaware 42-1491350 (State or other juris ...

Exhibit 99.1 Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Conference Call and Webcast Details The Company has scheduled a conference call and webcast for 4:30 p.m. ET today to discuss its financial results and ...

Thank you for taking my questions. Congratulations on the results. Our next question is from Yasmeen Rahimi with Piper Sandler. Rick Hawkins John McKew Yes. So, we will fully enroll that the full cohort at 12 months will absolutely come out next year -- in the first half of next year. And I think we have several key endocrine conferences that happen in the spring time with Pediatric Endocrine Society in the ENDO Meeting. And then later in the year, we'll have the SP meeting outside the US. Yasmeen Rahimi So ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2023. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) Delaware 42-1491350 (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2023. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) Delaware 42-1491350 (State or other juri ...

Company Participants Yasmeen Rahimi â Piper Sandler Leland Gershell â Oppenheimer Ed White â H.C. Wainwright Catherine Novack â Jones Trading Pete Stavropoulos â Cantor Fitzgerald Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experien ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2023. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) Delaware 42-1491350 (State or other jur ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2023 Results Conference Call May 3, 2023 4:30 PM ET Company Participants Lisa Miller - Senior Director, IR Rick Hawkins - CEO & Chairman Lori Lawley - CFO & Principal Accounting Officer David Karpf - Chief Medical Officer John McKew - Chief Scientific Officer & President Conference Call Participants Catherine Novack - Jones Trading Charles Duncan - Cantor Fitzgerald Leland Gershell - Oppenheimer Ed White - H.C. Wainwright & Co Yasmeen Rahimi - Piper Sandler Good afternoon ...